Sultan bin Ahmed visits Huawei R&D Centre and SMG in China
13.2.2026 18:52:00 CET | Business Wire | Press release
His Highness Sheikh Sultan bin Ahmed bin Sultan Al Qasimi, Deputy Ruler of Sharjah and Chairman of the Sharjah Media Council, visited the Huawei Research and Development Centre and Shanghai Media Group (SMG) in Shanghai, People’s Republic of China.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260213682693/en/

Sultan bin Ahmed visits Huawei R&D Centre and SMG in China (Photo: AETOSWire)
His Highness toured Huawei Village, which spans 2.2 million square metres and comprises over 100 buildings and laboratories, employing more than 30,000 staff. He observed the master plan of the village and its key facilities that support the company’s business strategy and product development. He also reviewed the specifications of the buildings, constructed to the highest standards, and the diverse services provided to employees, including restaurants, cafes, entertainment venues, and rest areas. The center also offers easy access via train, bus, boat, or electric bicycle.
His Highness then visited the R&D Centre, where he was briefed on its strategy and research and development framework. He learned about its specialised facilities and laboratories dedicated to developing technological solutions that support various vital sectors.
His Highness was briefed on the latest technologies and solutions in digital infrastructure serving the media sector, smart cities, security systems, data storage, and artificial intelligence, and the capabilities they offer to enhance the efficiency, quality, and sustainability of services. He also listened to an explanation of the most prominent research projects and Huawei's role in developing communications technologies, smart systems, and digital solutions, as well as its investment in human capital and attracting global expertise.
During a meeting with Huawei representatives, His Highness, emphasised the importance of leveraging global experiences in R&D. He noted Sharjah's commitment to keeping pace with technological advancements and employing technology to develop the media sector and enhance its regional and international competitiveness, thus solidifying its position as a leading centre for media innovation and content creation.
The meeting explored avenues for cooperation between the media sector in the Emirate of Sharjah and Huawei Research and Development, aiming to enhance the use of advanced technological solutions in developing media infrastructure. This includes leveraging artificial intelligence, cloud computing, and data analytics to support content creation and empower media professionals.
His Highness also visited Shanghai Media Group, which comprises eight television channels, eight radio stations, four magazines and newspapers, and eleven paid online channels, in addition to state-of-the-art studios and digital production and broadcasting centres that utilise intelligent content management systems.
His Highness was briefed on the group's four digital platforms, which include a platform for broadcasting television programmes and films, a radio broadcasting service across China, a platform for following local and international news live, and another for monitoring economic and financial transactions and serving those interested in markets and investment.
His Highness toured the studios, observing the broadcasting and live transmission technologies, and the outside broadcast vans used to cover major events, particularly sporting events such as the Olympic Games, with high-definition 4K filming and broadcasting technology.
His Highness held a meeting with the group's Director General and several officials, during which he commended the media management methods and discussed avenues for joint cooperation. He emphasised the importance of enhancing media content and promoting positive values. The Sharjah Media City project and the planned "Shams" studios were also presented.
These visits are part of an effort to strengthen cooperation with international technology institutions and companies, and to learn about best practices in innovation, scientific research, and technological development, thus supporting the media landscape in the Emirate of Sharjah.
His Highness was accompanied by a number of officials from media entities in the Emirate of Sharjah.
Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20260213682693/en/



Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom